Report Thumbnail
Product Code LP0914811474PA4
Published Date 2023/3/23
English123 PagesGlobal

Global Pharmaceutical Regulatory Affairs Market Growth (Status and Outlook) 2023-2029Pharmaceutical_LifeSciense Market


Report Thumbnail
Product Code LP0914811474PA4◆The Mar 2026 edition is also likely available. We will check with the publisher immediately.
Published Date 2023/3/23
English 123 PagesGlobal

Global Pharmaceutical Regulatory Affairs Market Growth (Status and Outlook) 2023-2029Pharmaceutical_LifeSciense Market



Abstract


Summary

Pharmaceutical Regulatory Affairs, or Pharma Regulatory Affairs, refers to the professionals who maintain regulations from within the industry. The pharmaceutical industry is the most regulated of all industries. Regulatory affairs professionals are key, but perhaps overlooked, players in drug development. They are the primary communications link between the company and agencies such as FDA, and they are responsible for keeping up with the increasing scope and complexity of regulations. In the pharmaceutical industry, regulatory affairs professionals have expertise in the legal and regulatory environments, as well as in clinical research protocols.
LPI (LP Information)' newest research report, the “Pharmaceutical Regulatory Affairs Industry Forecast” looks at past sales and reviews total world Pharmaceutical Regulatory Affairs sales in 2022, providing a comprehensive analysis by region and market sector of projected Pharmaceutical Regulatory Affairs sales for 2023 through 2029. With Pharmaceutical Regulatory Affairs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Pharmaceutical Regulatory Affairs industry.
This Insight Report provides a comprehensive analysis of the global Pharmaceutical Regulatory Affairs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Pharmaceutical Regulatory Affairs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Pharmaceutical Regulatory Affairs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Pharmaceutical Regulatory Affairs and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Pharmaceutical Regulatory Affairs.
The global Pharmaceutical Regulatory Affairs market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Pharmaceutical Regulatory Affairs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Pharmaceutical Regulatory Affairs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Pharmaceutical Regulatory Affairs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Pharmaceutical Regulatory Affairs players cover QuintilesIMS, LabCor, PAREXEL, Pharmaceutical Product Development, INC RESEARCH HOLDINGS, PRA Health Sciences, ICON, Charles River and Advent International, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Pharmaceutical Regulatory Affairs market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Regulatory Consulting
Legal Representation
Regulatory Writing & Publishing
Product Registration & Clinical Trial Application
Other Services
Segmentation by application
In-house
Outsourcing
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
QuintilesIMS
LabCor
PAREXEL
Pharmaceutical Product Development
INC RESEARCH HOLDINGS
PRA Health Sciences
ICON
Charles River
Advent International
WuXi AppTec, Inc.
Pharmaron Beijing Co., Ltd.
Hangzhou Tigermed Consulting Co.,Ltd.
Asymchem Laboratories (Tianjin) Co.,Ltd.
Accell Clinical Research, LLC.
GenPact Ltd.
Criterium, Inc.
Promedica International
Medpace
Covance
Freyr

Table of Contents

  • 1 Scope of the Report

    • 1.1 Market Introduction
    • 1.2 Years Considered
    • 1.3 Research Objectives
    • 1.4 Market Research Methodology
    • 1.5 Research Process and Data Source
    • 1.6 Economic Indicators
    • 1.7 Currency Considered
    • 1.8 Market Estimation Caveats
  • 2 Executive Summary

    • 2.1 World Market Overview
      • 2.1.1 Global Pharmaceutical Regulatory Affairs Market Size 2018-2029
      • 2.1.2 Pharmaceutical Regulatory Affairs Market Size CAGR by Region 2018 VS 2022 VS 2029
    • 2.2 Pharmaceutical Regulatory Affairs Segment by Type
      • 2.2.1 Regulatory Consulting
      • 2.2.2 Legal Representation
      • 2.2.3 Regulatory Writing & Publishing
      • 2.2.4 Product Registration & Clinical Trial Application
      • 2.2.5 Other Services
    • 2.3 Pharmaceutical Regulatory Affairs Market Size by Type
      • 2.3.1 Pharmaceutical Regulatory Affairs Market Size CAGR by Type (2018 VS 2022 VS 2029)
      • 2.3.2 Global Pharmaceutical Regulatory Affairs Market Size Market Share by Type (2018-2023)
    • 2.4 Pharmaceutical Regulatory Affairs Segment by Application
      • 2.4.1 In-house
      • 2.4.2 Outsourcing
    • 2.5 Pharmaceutical Regulatory Affairs Market Size by Application
      • 2.5.1 Pharmaceutical Regulatory Affairs Market Size CAGR by Application (2018 VS 2022 VS 2029)
      • 2.5.2 Global Pharmaceutical Regulatory Affairs Market Size Market Share by Application (2018-2023)
  • 3 Pharmaceutical Regulatory Affairs Market Size by Player

    • 3.1 Pharmaceutical Regulatory Affairs Market Size Market Share by Players
      • 3.1.1 Global Pharmaceutical Regulatory Affairs Revenue by Players (2018-2023)
      • 3.1.2 Global Pharmaceutical Regulatory Affairs Revenue Market Share by Players (2018-2023)
    • 3.2 Global Pharmaceutical Regulatory Affairs Key Players Head office and Products Offered
    • 3.3 Market Concentration Rate Analysis
      • 3.3.1 Competition Landscape Analysis
      • 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
    • 3.4 New Products and Potential Entrants
    • 3.5 Mergers & Acquisitions, Expansion
  • 4 Pharmaceutical Regulatory Affairs by Regions

    • 4.1 Pharmaceutical Regulatory Affairs Market Size by Regions (2018-2023)
    • 4.2 Americas Pharmaceutical Regulatory Affairs Market Size Growth (2018-2023)
    • 4.3 APAC Pharmaceutical Regulatory Affairs Market Size Growth (2018-2023)
    • 4.4 Europe Pharmaceutical Regulatory Affairs Market Size Growth (2018-2023)
    • 4.5 Middle East & Africa Pharmaceutical Regulatory Affairs Market Size Growth (2018-2023)
  • 5 Americas

    • 5.1 Americas Pharmaceutical Regulatory Affairs Market Size by Country (2018-2023)
    • 5.2 Americas Pharmaceutical Regulatory Affairs Market Size by Type (2018-2023)
    • 5.3 Americas Pharmaceutical Regulatory Affairs Market Size by Application (2018-2023)
    • 5.4 United States
    • 5.5 Canada
    • 5.6 Mexico
    • 5.7 Brazil
  • 6 APAC

    • 6.1 APAC Pharmaceutical Regulatory Affairs Market Size by Region (2018-2023)
    • 6.2 APAC Pharmaceutical Regulatory Affairs Market Size by Type (2018-2023)
    • 6.3 APAC Pharmaceutical Regulatory Affairs Market Size by Application (2018-2023)
    • 6.4 China
    • 6.5 Japan
    • 6.6 Korea
    • 6.7 Southeast Asia
    • 6.8 India
    • 6.9 Australia
  • 7 Europe

    • 7.1 Europe Pharmaceutical Regulatory Affairs by Country (2018-2023)
    • 7.2 Europe Pharmaceutical Regulatory Affairs Market Size by Type (2018-2023)
    • 7.3 Europe Pharmaceutical Regulatory Affairs Market Size by Application (2018-2023)
    • 7.4 Germany
    • 7.5 France
    • 7.6 UK
    • 7.7 Italy
    • 7.8 Russia
  • 8 Middle East & Africa

    • 8.1 Middle East & Africa Pharmaceutical Regulatory Affairs by Region (2018-2023)
    • 8.2 Middle East & Africa Pharmaceutical Regulatory Affairs Market Size by Type (2018-2023)
    • 8.3 Middle East & Africa Pharmaceutical Regulatory Affairs Market Size by Application (2018-2023)
    • 8.4 Egypt
    • 8.5 South Africa
    • 8.6 Israel
    • 8.7 Turkey
    • 8.8 GCC Countries
  • 9 Market Drivers, Challenges and Trends

    • 9.1 Market Drivers & Growth Opportunities
    • 9.2 Market Challenges & Risks
    • 9.3 Industry Trends
  • 10 Global Pharmaceutical Regulatory Affairs Market Forecast

    • 10.1 Global Pharmaceutical Regulatory Affairs Forecast by Regions (2024-2029)
      • 10.1.1 Global Pharmaceutical Regulatory Affairs Forecast by Regions (2024-2029)
      • 10.1.2 Americas Pharmaceutical Regulatory Affairs Forecast
      • 10.1.3 APAC Pharmaceutical Regulatory Affairs Forecast
      • 10.1.4 Europe Pharmaceutical Regulatory Affairs Forecast
      • 10.1.5 Middle East & Africa Pharmaceutical Regulatory Affairs Forecast
    • 10.2 Americas Pharmaceutical Regulatory Affairs Forecast by Country (2024-2029)
      • 10.2.1 United States Pharmaceutical Regulatory Affairs Market Forecast
      • 10.2.2 Canada Pharmaceutical Regulatory Affairs Market Forecast
      • 10.2.3 Mexico Pharmaceutical Regulatory Affairs Market Forecast
      • 10.2.4 Brazil Pharmaceutical Regulatory Affairs Market Forecast
    • 10.3 APAC Pharmaceutical Regulatory Affairs Forecast by Region (2024-2029)
      • 10.3.1 China Pharmaceutical Regulatory Affairs Market Forecast
      • 10.3.2 Japan Pharmaceutical Regulatory Affairs Market Forecast
      • 10.3.3 Korea Pharmaceutical Regulatory Affairs Market Forecast
      • 10.3.4 Southeast Asia Pharmaceutical Regulatory Affairs Market Forecast
      • 10.3.5 India Pharmaceutical Regulatory Affairs Market Forecast
      • 10.3.6 Australia Pharmaceutical Regulatory Affairs Market Forecast
    • 10.4 Europe Pharmaceutical Regulatory Affairs Forecast by Country (2024-2029)
      • 10.4.1 Germany Pharmaceutical Regulatory Affairs Market Forecast
      • 10.4.2 France Pharmaceutical Regulatory Affairs Market Forecast
      • 10.4.3 UK Pharmaceutical Regulatory Affairs Market Forecast
      • 10.4.4 Italy Pharmaceutical Regulatory Affairs Market Forecast
      • 10.4.5 Russia Pharmaceutical Regulatory Affairs Market Forecast
    • 10.5 Middle East & Africa Pharmaceutical Regulatory Affairs Forecast by Region (2024-2029)
      • 10.5.1 Egypt Pharmaceutical Regulatory Affairs Market Forecast
      • 10.5.2 South Africa Pharmaceutical Regulatory Affairs Market Forecast
      • 10.5.3 Israel Pharmaceutical Regulatory Affairs Market Forecast
      • 10.5.4 Turkey Pharmaceutical Regulatory Affairs Market Forecast
      • 10.5.5 GCC Countries Pharmaceutical Regulatory Affairs Market Forecast
    • 10.6 Global Pharmaceutical Regulatory Affairs Forecast by Type (2024-2029)
    • 10.7 Global Pharmaceutical Regulatory Affairs Forecast by Application (2024-2029)
  • 11 Key Players Analysis

    • 11.1 QuintilesIMS
      • 11.1.1 QuintilesIMS Company Information
      • 11.1.2 QuintilesIMS Pharmaceutical Regulatory Affairs Product Offered
      • 11.1.3 QuintilesIMS Pharmaceutical Regulatory Affairs Revenue, Gross Margin and Market Share (2018-2023)
      • 11.1.4 QuintilesIMS Main Business Overview
      • 11.1.5 QuintilesIMS Latest Developments
    • 11.2 LabCor
      • 11.2.1 LabCor Company Information
      • 11.2.2 LabCor Pharmaceutical Regulatory Affairs Product Offered
      • 11.2.3 LabCor Pharmaceutical Regulatory Affairs Revenue, Gross Margin and Market Share (2018-2023)
      • 11.2.4 LabCor Main Business Overview
      • 11.2.5 LabCor Latest Developments
    • 11.3 PAREXEL
      • 11.3.1 PAREXEL Company Information
      • 11.3.2 PAREXEL Pharmaceutical Regulatory Affairs Product Offered
      • 11.3.3 PAREXEL Pharmaceutical Regulatory Affairs Revenue, Gross Margin and Market Share (2018-2023)
      • 11.3.4 PAREXEL Main Business Overview
      • 11.3.5 PAREXEL Latest Developments
    • 11.4 Pharmaceutical Product Development
      • 11.4.1 Pharmaceutical Product Development Company Information
      • 11.4.2 Pharmaceutical Product Development Pharmaceutical Regulatory Affairs Product Offered
      • 11.4.3 Pharmaceutical Product Development Pharmaceutical Regulatory Affairs Revenue, Gross Margin and Market Share (2018-2023)
      • 11.4.4 Pharmaceutical Product Development Main Business Overview
      • 11.4.5 Pharmaceutical Product Development Latest Developments
    • 11.5 INC RESEARCH HOLDINGS
      • 11.5.1 INC RESEARCH HOLDINGS Company Information
      • 11.5.2 INC RESEARCH HOLDINGS Pharmaceutical Regulatory Affairs Product Offered
      • 11.5.3 INC RESEARCH HOLDINGS Pharmaceutical Regulatory Affairs Revenue, Gross Margin and Market Share (2018-2023)
      • 11.5.4 INC RESEARCH HOLDINGS Main Business Overview
      • 11.5.5 INC RESEARCH HOLDINGS Latest Developments
    • 11.6 PRA Health Sciences
      • 11.6.1 PRA Health Sciences Company Information
      • 11.6.2 PRA Health Sciences Pharmaceutical Regulatory Affairs Product Offered
      • 11.6.3 PRA Health Sciences Pharmaceutical Regulatory Affairs Revenue, Gross Margin and Market Share (2018-2023)
      • 11.6.4 PRA Health Sciences Main Business Overview
      • 11.6.5 PRA Health Sciences Latest Developments
    • 11.7 ICON
      • 11.7.1 ICON Company Information
      • 11.7.2 ICON Pharmaceutical Regulatory Affairs Product Offered
      • 11.7.3 ICON Pharmaceutical Regulatory Affairs Revenue, Gross Margin and Market Share (2018-2023)
      • 11.7.4 ICON Main Business Overview
      • 11.7.5 ICON Latest Developments
    • 11.8 Charles River
      • 11.8.1 Charles River Company Information
      • 11.8.2 Charles River Pharmaceutical Regulatory Affairs Product Offered
      • 11.8.3 Charles River Pharmaceutical Regulatory Affairs Revenue, Gross Margin and Market Share (2018-2023)
      • 11.8.4 Charles River Main Business Overview
      • 11.8.5 Charles River Latest Developments
    • 11.9 Advent International
      • 11.9.1 Advent International Company Information
      • 11.9.2 Advent International Pharmaceutical Regulatory Affairs Product Offered
      • 11.9.3 Advent International Pharmaceutical Regulatory Affairs Revenue, Gross Margin and Market Share (2018-2023)
      • 11.9.4 Advent International Main Business Overview
      • 11.9.5 Advent International Latest Developments
    • 11.10 WuXi AppTec, Inc.
      • 11.10.1 WuXi AppTec, Inc. Company Information
      • 11.10.2 WuXi AppTec, Inc. Pharmaceutical Regulatory Affairs Product Offered
      • 11.10.3 WuXi AppTec, Inc. Pharmaceutical Regulatory Affairs Revenue, Gross Margin and Market Share (2018-2023)
      • 11.10.4 WuXi AppTec, Inc. Main Business Overview
      • 11.10.5 WuXi AppTec, Inc. Latest Developments
    • 11.11 Pharmaron Beijing Co., Ltd.
      • 11.11.1 Pharmaron Beijing Co., Ltd. Company Information
      • 11.11.2 Pharmaron Beijing Co., Ltd. Pharmaceutical Regulatory Affairs Product Offered
      • 11.11.3 Pharmaron Beijing Co., Ltd. Pharmaceutical Regulatory Affairs Revenue, Gross Margin and Market Share (2018-2023)
      • 11.11.4 Pharmaron Beijing Co., Ltd. Main Business Overview
      • 11.11.5 Pharmaron Beijing Co., Ltd. Latest Developments
    • 11.12 Hangzhou Tigermed Consulting Co.,Ltd.
      • 11.12.1 Hangzhou Tigermed Consulting Co.,Ltd. Company Information
      • 11.12.2 Hangzhou Tigermed Consulting Co.,Ltd. Pharmaceutical Regulatory Affairs Product Offered
      • 11.12.3 Hangzhou Tigermed Consulting Co.,Ltd. Pharmaceutical Regulatory Affairs Revenue, Gross Margin and Market Share (2018-2023)
      • 11.12.4 Hangzhou Tigermed Consulting Co.,Ltd. Main Business Overview
      • 11.12.5 Hangzhou Tigermed Consulting Co.,Ltd. Latest Developments
    • 11.13 Asymchem Laboratories (Tianjin) Co.,Ltd.
      • 11.13.1 Asymchem Laboratories (Tianjin) Co.,Ltd. Company Information
      • 11.13.2 Asymchem Laboratories (Tianjin) Co.,Ltd. Pharmaceutical Regulatory Affairs Product Offered
      • 11.13.3 Asymchem Laboratories (Tianjin) Co.,Ltd. Pharmaceutical Regulatory Affairs Revenue, Gross Margin and Market Share (2018-2023)
      • 11.13.4 Asymchem Laboratories (Tianjin) Co.,Ltd. Main Business Overview
      • 11.13.5 Asymchem Laboratories (Tianjin) Co.,Ltd. Latest Developments
    • 11.14 Accell Clinical Research, LLC.
      • 11.14.1 Accell Clinical Research, LLC. Company Information
      • 11.14.2 Accell Clinical Research, LLC. Pharmaceutical Regulatory Affairs Product Offered
      • 11.14.3 Accell Clinical Research, LLC. Pharmaceutical Regulatory Affairs Revenue, Gross Margin and Market Share (2018-2023)
      • 11.14.4 Accell Clinical Research, LLC. Main Business Overview
      • 11.14.5 Accell Clinical Research, LLC. Latest Developments
    • 11.15 GenPact Ltd.
      • 11.15.1 GenPact Ltd. Company Information
      • 11.15.2 GenPact Ltd. Pharmaceutical Regulatory Affairs Product Offered
      • 11.15.3 GenPact Ltd. Pharmaceutical Regulatory Affairs Revenue, Gross Margin and Market Share (2018-2023)
      • 11.15.4 GenPact Ltd. Main Business Overview
      • 11.15.5 GenPact Ltd. Latest Developments
    • 11.16 Criterium, Inc.
      • 11.16.1 Criterium, Inc. Company Information
      • 11.16.2 Criterium, Inc. Pharmaceutical Regulatory Affairs Product Offered
      • 11.16.3 Criterium, Inc. Pharmaceutical Regulatory Affairs Revenue, Gross Margin and Market Share (2018-2023)
      • 11.16.4 Criterium, Inc. Main Business Overview
      • 11.16.5 Criterium, Inc. Latest Developments
    • 11.17 Promedica International
      • 11.17.1 Promedica International Company Information
      • 11.17.2 Promedica International Pharmaceutical Regulatory Affairs Product Offered
      • 11.17.3 Promedica International Pharmaceutical Regulatory Affairs Revenue, Gross Margin and Market Share (2018-2023)
      • 11.17.4 Promedica International Main Business Overview
      • 11.17.5 Promedica International Latest Developments
    • 11.18 Medpace
      • 11.18.1 Medpace Company Information
      • 11.18.2 Medpace Pharmaceutical Regulatory Affairs Product Offered
      • 11.18.3 Medpace Pharmaceutical Regulatory Affairs Revenue, Gross Margin and Market Share (2018-2023)
      • 11.18.4 Medpace Main Business Overview
      • 11.18.5 Medpace Latest Developments
    • 11.19 Covance
      • 11.19.1 Covance Company Information
      • 11.19.2 Covance Pharmaceutical Regulatory Affairs Product Offered
      • 11.19.3 Covance Pharmaceutical Regulatory Affairs Revenue, Gross Margin and Market Share (2018-2023)
      • 11.19.4 Covance Main Business Overview
      • 11.19.5 Covance Latest Developments
    • 11.20 Freyr
      • 11.20.1 Freyr Company Information
      • 11.20.2 Freyr Pharmaceutical Regulatory Affairs Product Offered
      • 11.20.3 Freyr Pharmaceutical Regulatory Affairs Revenue, Gross Margin and Market Share (2018-2023)
      • 11.20.4 Freyr Main Business Overview
      • 11.20.5 Freyr Latest Developments
  • 12 Research Findings and Conclusion

USD 3,660 or Partial Purchase
*Prices are subject to change by the publisher.
© 2026 ShareFair Inc.